Procaps Group

About Us

Procaps Group, S.A. ("Procaps Group") (NASDAQ: PROC) is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. Procaps has a direct presence in 13 countries in the Americas and more than 5,300 collaborators working under a sustainable model. Procaps develops, manufactures, and markets over the counter (OTC) pharmaceutical products and prescription pharmaceutical drugs (Rx), nutritional supplements and high-potency clinical solutions.

ESG Report 2021

Committed to Innovation for a Healthier World

Read more
ESG Report

Press Realease

Procaps Issues Shareholder Letter and Provides Preliminary Fiscal Year 2022 Financial Results and 2023 Guidance

Reports Preliminary Financial Estimates for Net Revenue and Adjusted EBITDA for Full Year 2022 Realigns Board of Directors to Focus on Profitable Growth Announces $5M+ Share Repurchase Program Commences $15MM Cost Reduction Plan to Improve Margins and Financial Performance 20-F & Conference Call

February 13, 2023 

Read more

Pharmaceutical Group
dedicated to delivering
health and nutrition

We employ over 5,300 people across 13 countries
 

Our products reach 
50+ markets

Virtual Tour